A leading incubator for cancer treatment innovations with a focus on the diagnosis and treatment of multiple myeloma, other B-cell malignancies and related disorders.
- ONCOtracker, Inc. is a West Hollywood-based oncology company pursuing intellectual property for innovative treatments leading to dramatically improved outcomes.
- We have exclusive rights to a Serum B-Cell Maturation Antigen (sBCMA) blood test, which is being developed to monitor tumor burden and predict the therapeutic outcome of multiple myeloma patients.
- sBCMA is being investigated for clinical application in chronic lymphocytic leukemia, B-cell lymphoma and select solid tumor malignancies.
- ONCOtracker has intellectual property related to novel treatment approaches for multiple myeloma, which are being pursued in ongoing clinical trials.